DNA fragmentation damage as a predictive marker for diabetic nephropathy in Type II diabetes mellitus

Nourhan Soliman*, Mohamed El-Shabrawi** and Seham Omar *

*Clinical Pathology Department, Suez Canal University, Ismailia, Egypt
**Internal Medicine Department, Suez Canal University, Ismailia, Egypt
*Corresponding author, email: zeinash2003@yahoo.com

Introduction
Diabetes mellitus is a real problem that influences the world as a whole and Egypt in particular. The World Health Organization estimated that the world prevalence of DM among adults was 6.4%, affecting 285 million adults in 2010 with an expected rise to 7.7%, affecting 439 million adults, by 2030. Between 2010 and 2030, there will be a 69% increase in numbers of adults with diabetes in developing and 20% increase in developed countries. The current prevalence of diabetes in adults in the region is estimated to be around 9.2%. Of the 34 million people affected by diabetes, nearly 17 million were undiagnosed and therefore, they would be at considerable risk of diabetic complications and poor health outcomes.

Diabetic nephropathy is a major cause of end-stage renal disease (ESRD) worldwide. Prevalence of diabetic nephropathy gradually increased from 8.9% in 1996, to 14.5% in 2001. The mean age of patients with diabetic nephropathy-related ESRD was significantly higher than that of ESRD from other causes. Mortality was also significantly higher in diabetic patients with diabetic nephropathy-related ESRD compared to other causes of ESRD. In diabetic nephropathy there is a progressive decline in the glomerular filtration rate, characterised by glomerular hyperfiltration, glomerular and tubular epithelial hypertrophy, increased urinary albumin excretion, increased basement membrane thickness and mesangial expansion with the accumulation of extracellular matrix proteins (ECM). Increased renal advanced glycation end-products (AGE) in diabetic patients have been linked to structural abnormality observed in diabetic nephropathy such as mesangial expansion, glomerular basement membrane thickening and tubular-interstitial fibrosis. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are the terms collectively describing free radicals and other non-radical reactive derivatives, also called oxidants. Biological free radicals are highly unstable molecules that are products of normal cellular metabolism. They have electrons available to react with various organic substrates such as lipids, proteins and deoxyribonucleic acid (DNA). Free radicals are well recognised for playing a dual role as both deleterious and beneficial species, since they can be either harmful or beneficial to living systems.

Numerous experimental evidences have highlighted a direct link between oxidative stress and diabetes through the measurement of oxidative stress biomarkers in both diabetic patients and rodents. A hyperglycaemic state can lead to an increase in the levels of oxidative DNA damage markers such as 8-hydroxy-2′-deoxyguanosine (8-OHdG), 8-oxo-7, 8-dihydro-2′-deoxyguanosine (8-oxodG), lipid-peroxidation products (TBARS), protein oxidation products such as nitrotyrosine and carbonyl. In the meantime they can all lower the activity of antioxidant enzymes. Due to the ability of ROS to directly oxidise and damage DNA, proteins and lipids, free radicals are believed to play a key role in the onset and progression of late diabetic complications.
During the last decade, capillary electrophoresis applied to the biological systems is emerging as a new bio-analytical method with the advantages of fast analysis time, automation, on-column injection and detection, reproducible analysis and high resolving power for the separation testing of double-stranded (ds) DNA fragments.\textsuperscript{6,11} It is a sensitive, simple, inexpensive and rapid method that can be used to detect DNA damage to the individual cells and reveal the presence of double-strand breaks, single-strand breaks and alkali-labile sites.\textsuperscript{11,12}

Therefore, this study was planned to focus on the relationship between frequency occurrence of DNA damage in type II diabetic individuals and the presence of diabetic nephropathy, with assessment of its validity as a possible diagnostic biomarker for detection of diabetic nephropathy.

**Patients and methods**

This is a cross-sectional study that was carried out in the diabetes outpatient clinic and clinical pathology unit at Suez Canal University, Egypt. The study population consisted of 1009 consecutive patients with diabetic nephropathy (Group 1), 100 age-matched diabetic patients without nephropathy (Group 2) and 100 healthy volunteers (Group 3) as controls. Data were collected after obtaining informed consent from all subjects using an interview questionnaire. All individuals were subjected to a complete history, physical examination (height, weight and BMI were calculated) and laboratory investigations. Groups 1 and 2 comprised patients known to have type II diabetes mellitus diagnosed according to ADA guidelines.

Diabetic nephropathy was diagnosed if the patient had positive urinary albumin determined by immunoassay using a morning spot urine, urinary albumin/creatinine ratio ranging from 30 to 299 mg/g creatinine in two or more of three specimens or either urinary albumin excretion rate of 30–299 mg/24 hr urine collection or 20–199 μg/min in timed urine collection.

Patients with either type I diabetes mellitus who refused to participate, with chronic cardiovascular, lung or liver disease or micro-albuminuria associated with a non-diabetic cause were excluded from the study.

A 10 ml blood specimen was collected from each patient in the first session and 3 ml in the second session as follows. In the first session 4 ml of blood was collected and divided into two EDTA tubes, one for DNA extraction and the other for glycated haemoglobin measurement, while 3 ml of blood was collected after 8 h fasting in a sterile plain tube for measuring of fasting blood sugar; 3.0 ml of blood was collected after 12 h fasting in a sterile plain tube for measuring total cholesterol, triglycerides, HDL-cholesterol and HbA1c among diabetic patients in groups 1 and 2 comprised patients known to have type II diabetes mellitus diagnosed according to ADA guidelines.

| Smok- ing* | Negative, n (%) | 70 (70%) | 70 (70%) | 100 (100%) |
|-----------|----------------|----------|----------|------------|
| Family history | Negative, n (%) | 61 (61%) | 60 (60%) | 90 (90%)  |
| Positive, n (%) | 39 (39%) | 40 (40%) | 10 (10%) |

Lipid profile, micro-albuminuria, FBS, PPS and HbA1c were analysed using a Cobas 6000 auto-analyser (Roche Diagnostics GmbH, Mannheim, Germany).

**DNA extraction and fragmentation analysis**

Genomic DNA was extracted from peripheral blood using avcommercially available spin-column technique kit for DNA extraction (QIAamp®DNA Blood Mini Kit) according to the manufacturer’s instructions (QIAGEN, Inc, Hilden, Germany). DNA yield and purity was assessed using a spectro-photometrically Thermo Scientific NanoDrop™ Spectrophotometer (Nanodrop) (Thermo Fisher Scientific Inc, Waltham, MA, USA).

Analysis of DNA degradation was done using QIAxcel DNA Kits for automated analysis of DNA fragments using a QIAxcel capillary electrophoresis instrument that provides robust results for nucleic acid concentrations as low as 0.1 ng/μl and accurate analyses with resolution down to 3–5 bp. After processing, the data are displayed as an electropherogram or gel image.

**Results**

The study groups were matched for gender distribution. Regarding age, the three groups were divided into 46.41 ± 14.47 years, 52.95 ± 13.25 years and 33.8 ± 10.45 years respectively. The mean body mass index was 31.31 ± 4.57 kg/m\(^2\) in group 1 compared with 30.5 ± 4.78 kg/m\(^2\) and 26.6 ± 5.02 kg/m\(^2\) in groups 2 and 3 respectively (\(p = 0.008\) and 0.009). The mean duration of diabetes was 5.57 ± 2.5 years in group 1 compared with 4.35 ± 1.95 years in group 2 (Table 1).

| Demographic data of studied population |
|---------------------------------------|
| With nephropathy | Without nephropathy | Control |
| Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) | Mean ± SD | Median (IQR) |
| Age | 46.41 ± 14.47 | 52.95 ± 13.25 | 33.8 ± 10.45 |
| | 48 (22) | 57 (20) | 33 (11) |
| Duration of DM (years) | 5.57 ± 2.5 | 4.35 ± 1.95 | – |
| | 5 (3) | 4.5 (3) | – |
| Sex | Male, n (%) | 24 (24%) | 40 (40%) | 50 (50%) |
| | Female, n (%) | 76 (76%) | 60 (60%) | 50 (50%) |
| Smoking* | Negative, n (%) | 70 (70%) | 70 (70%) | 100 (100%) |
| Family history | Negative, n (%) | 61 (61%) | 60 (60%) | 90 (90%) |
| | Positive, n (%) | 39 (39%) | 40 (40%) | 10 (10%) |
Multivariate analysis showed that the positive oxidative DNA damage test (OR 1.58, \(p = 0.02\)) and the duration of current DM (OR 1.48, \(p = 0.004\)) were the only independent factors contributing to the occurrence of diabetic nephropathy. The ROC curve for quantity of DNA fragmentation in relation to diabetic nephropathy was studied. The cut-off point of DNA fragmentation for diagnosis of diabetic nephropathy was 1 strand break with an area under the curve of 0.7466, which provides a sensitivity of 71.43% and a specificity of 70.00%.

**Discussion**

The present study reported increased oxidative DNA damage in peripheral blood leucocytes of diabetic nephropathy compared with non-nephropathy patients. Moreover, DNA fragmentation was exclusively found in more than two-thirds of diabetic nephropathy patients compared with none of the healthy control group. Previous studies concerning DNA damage and diabetes revealed contradictory results. Several studies showed an increased extent of DNA damage in type II diabetic patients compared with controls. On the other hand, other studies showed a lack of association between diabetes and increased DNA damage levels. The discrepancy between different studies is possibly due to differences in glycaemic control, patient age, and duration of diabetes, treatment methods and techniques used to measure oxidative stress.

Goodarzi et al.\(^{12}\) reported on a significant positive correlation between urinary 8-OHdG, a biomarker of oxidative DNA damage, and both fasting blood glucose and Hba1c. In the present study, there was no correlation between DNA damage and either blood sugar or Hba1c. Theoretically speaking, hyperglycaemia causes glucose auto-oxidation, glycation of proteins, activation of polyol metabolism and subsequent formation of ROS. It has also been demonstrated that hyperglycaemia is associated with an increased production of free radicals in the mitochondria and may contribute to greater DNA damage.\(^{15}\)

The study did not find any statistically significant difference between duration of diabetes and DNA damage. This has been reported by other authors. In diabetes, Ibarra-Costilla and his colleagues\(^{11}\) suggested that long-term chronic exposure causes adaptation of response to damage and produces less genetic damage than initial exposure.

One of the complications of diabetes is nephropathy. Diabetic nephropathy is associated with DNA damage that increases with progression of nephropathy. In the current study, there was a statistically significant positive correlation between quantitative DNA damage and severity of micro-albuminuria. Such a finding was also supported by Hinokio et al.,\(^{14}\) who reported a significant positive correlation between 8-oxo, 2′-deoxy-guanosine in urine as a marker for oxidative stress and micro-albuminuria among type II diabetic patients.

In this study, there is no statistically significant correlation between DNA damage and either serum total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol or BMI. Other studies have revealed increased DNA damage in obesity with a significant positive correlation with cholesterol, triglycerides and LDL-cholesterol. Also, DNA damage was present in atherosclerotic plaques and in circulating cells of patients with atherosclerosis.\(^{15}\) It is not known whether DNA damage in diabetes directly

---

**Table 2: Background characteristics of studied population**

| Lab and exam characteristics | With nephropathy | Without nephropathy | Control |
|-----------------------------|------------------|---------------------|---------|
|                             | Mean ± SD       | Median (IQR)       | Mean ± SD       | Median (IQR)       | Mean ± SD       | Median (IQR)       |
| BMI (kg/m²)                 | 31.31 ± 4.57    | 30 (4)             | 30.5 ± 4.78     | 29.5 (6)           | 26.6 ± 5.02     | 27 (4)             |
| Cholesterol (mg/dl)         | 209.35 ± 8.19   | 202 (61)           | 214.65 ± 48.54  | 208 (46.5)         | 156.5 ± 20.07   | 150 (30)           |
| TG (mg/dl)                  | 174 ± 8.74      | 164 (118)          | 146.15 ± 68.29  | 127.5 (90.5)       | 63.1 ± 20.98    | 62 (31)            |
| HDL (mg/dl)                 | 45.43 ± 13.69   | 3 (14)             | 44.9 ± 12.4     | 46.5 (19)          | 54 ± 13.06      | 50.5 (20)          |
| LDL (mg/dl)                 | 128.65 ± 36.89  | 123 (51)           | 140.5 ± 46.34   | 141 (25)           | 84.6 ± 26.25    | 80 (47)            |
| FBS (mg/dl)                 | 191.31 ± 85.33  | 164 (116)          | 158.2 ± 65.21   | 144 (100.5)        | 87.7 ± 8.92     | 85 (7)             |
| PP (mg/dl)                  | 298.55 ± 102.74 | 272 (181)          | 258.8 ± 107.78  | 261 (178.5)        | 121.3 ± 14.94   | 117.5 (15)         |
| HbA1C (%)                   | 8.96 ± 2.14     | 8.8 (3.2)          | 8.74 ± 1.98     | 8.85 (2.4)         | 5.24 ± 0.43     | 5.2 (0.4)          |
| ALB (mg/l)                  | 64.98 ± 39.38   | 50 (35)            | 16.2 ± 7.04     | 16 (10.5)          | 16.5 ± 6.6      | 15 (7)             |
| Fundus Negative, n (%)      | 45 (45%)        | 35 (35%)           | 90 (90%)        | 65 (85%)           | 10 (10%)        | 100 (100%)         |
| Exam Positive, n (%)        | 55 (55%)        | 65 (85%)           | 100 (100%)      | 100 (100%)         | 0 (0%)          |
| DNA Fragmentation Negative, n (%) | 29 (29%) | 55 (55%) | 100 (100%) | 0 (0%) |
Table 3: Background characteristics of DNA fragmentation in positive and negative diabetics

| Patient characteristics | DNA fragmentation | p-value |
|-------------------------|-------------------|---------|
|                         | Negative Mean ± SD | Positive Mean ± SD |
|                         | Median (IQR)       | Median (IQR)     |
| Age (years)             | 51.08 ± 14.02      | 46.73 ± 14.44    | 0.233 |
|                         | 54 (18)            | 45 (22)          |       |
| Duration (years)        | 5.08 ± 2           | 5.3 ± 2.63       | 0.845 |
|                         | 5 (2)              | 5 (4)            |       |
| BMI (kg/m²)             | 31.24 ± 5.26       | 30.98 ± 4.27     | 0.866 |
|                         | 31 (7)             | 30 (4.5)         |       |
| Sex                     | Male, n (%)        | Female, n (%)    | 0.215 |
|                         | 20 (20%)           | 34 (34%)         |       |
|                         | 80 (80%)           | 66 (66%)         |       |
| Family                  | Negative, n (%)    | 52 (52%)         | 0.255 |
|                         | 65 (65%)           |                 |       |
| History                 | Positive, n (%)    | 48 (48%)         | 0.05  |
|                         | 35 (34%)           |                 |       |
| Smoking                 | Negative, n (%)    | 84 (84%)         | 0.38  |
|                         | 62 (62%)           |                 |       |
|                         | 16 (16%)           | 38 (38%)         |       |
| Cholesterol (mg/dl)     | 212.64 ± 37.23     | 209.89 ± 53.53   | 0.649 |
|                         | 203 (46)           | 202 (59)         |       |
| TG (mg/dl)              | 172.76 ± 67.12     | 162.16 ± 91.1    | 0.289 |
|                         | 166 (90)           | 139 (157)        |       |
| HDL (mg/dl)             | 43.2 ± 10.47       | 46.45 ± 14.56    | 0.198 |
|                         | 39 (10)            | 46.5 (16.5)      |       |
| LDL (mg/dl)             | 132.04 ± 30.17     | 132.11 ± 44.79   | 0.97  |
|                         | 134 (29)           | 128 (44.5)       |       |
| FBS (mg/dl)             | 168.4 ± 69.96      | 189.27 ± 86.46   | 0.372 |
|                         | 138 (75)           | 167.5 (115.5)    |       |
| PP (mg/dl)              | 281.72 ± 109.38    | 290.05 ± 103.61  | 0.658 |
|                         | 260 (160)          | 269 (161)        |       |
| HbA1C (%)               | 8.7 ± 1.88         | 9 ± 2.21         | 0.649 |
|                         | 8.5 (2.6)          | 8.95 (3.3)       |       |
| ALB (mg/l)              | 37.64 ± 25.21      | 58.34 ± 45.01    | 0.056 |
|                         | 40 (27)            | 44 (37.5)        |       |
| Fundus                  | Negative, n (%)    | 32 (32%)         | 0.4   |
|                         | 47 (47%)           |                 |       |
| Exam                    | Positive, n (%)    | 68 (68%)         | 0.53  |

Mann–Whitney test used for quantitative data and chi-square test for qualitative data.

Promotes atherosclerosis, or is a by-product of dyslipidaemia of diabetes.

Conclusion
Type II diabetic patients have more liability to oxidative DNA damage in general with a significantly higher frequency in diabetic nephropathy compared with non-nephropathy patients. DNA fragmentation analysis can be used as a valuable diagnostic biomarker for diabetic nephropathy.

Disclosure statement – No potential conflict of interest was reported by the authors.

References
1. Majeed A, El-Sayed A, Khoja T, et al. Diabetes in the middle-East and North Africa. Diabetes Res Clin Pract 2014 Feb; 103(2):218–22. doi:10.1016/j.diabres.2013.11.008.
2. Soliman A. Diabetes mellitus in Egypt in short. J Diabetes Metab. 2013;4:318. doi:10.4172/2155-6156.1000318 World Health Organization.
3. Afifi A, El Setouhy M, El Sharkawy M, et al. Diabetic nephropathy as a cause of end-stage renal disease in Egypt: a six-year study. East Mediterr Health J. 2004 Jul–Sep;10(4–5):620–6.
4. Jain M. Histopathological changes in diabetic kidney disease. Clinical Queries: Nephrology 2012;1(2):127–33. https://doi.org/10.1016/S2211-9477(12)70006-7
5. Yamagishi5,Matsu5,T.Advancedglycationendproducts,oxidativestress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101–8. https://doi.org/10.4161/oxidm.3.2.11148
6. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84. https://doi.org/10.1016/j.biocel.2006.07.001
7. Inoguchi T, Li P, Umeda F, et al. Histopathological changes in diabetic kidney disease. Clin Queries: Nephrol 2012;1(2):127–33.
8. Lee Yun Jung, Suh K, Choi M, et al. Kaempferol protects HIT-T15 pancreatic beta cells from 2-deoxy-D-ribose-induced oxidative damage. Phytother Res. 2010;24:419–23. https://doi.org/10.1002/ptr.v243
9. Rosen P, Nawroth P, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes/Metab Res Rev. 2001;17(3):189–212. https://doi.org/10.1002/(ISSN)1520-7560
10. Blasiak J, Arabiski M, Krupa R. DNA damage and repair in type 2 diabetes mellitus. Mutation Res/Fundamental Molecular Mechanisms of Mutagenesis. 2004;554:297–304. https://doi.org/10.1016/j.mrfmmm.2004.05.011
11. Ibarra-Costilla E, Cerda-Flores R, DaVilla- Rodriguez M. DNA damage evaluated by comet assay in Mexican patients with type IIdiabetes mellitus. Acta Diabetol. 2009. doi:10.1007/s00592-009-0149-9.
12. Goodarzi M, Navidi A, Rezaei M. Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal. 2010;24(2):72–76. https://doi.org/10.1002/jcla.v24:2
13. Robertson R. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279:42351–54. https://doi.org/10.1074/jbc.R400019200
14. Hinokio Y, Suzuki S, Hirai M. Oxidative DNA damage in diabetes mellitus: its association with diabetic complications. Diabetologia. 2012;55:1046–53. https://doi.org/10.1007/s00125012-10008-7
15. Andressi M, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med 2003;13:270–5. https://doi.org/10.1016/S1050-1738(03)00109-9

Received: 22-10-2017 Accepted: 26-01-2018